LEXINGTON, Mass., July 29, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on July 22, 2022, the independent Compensation Committee of the Board of Directors of Curis approved the grant of an inducement stock option to purchase a total of 540,000 shares of Curis common stock to a new employee, with a grant date of July 26, 2022, which is the employee's date of hire (the "Inducement Grant").
Read more at prnewswire.comCuris Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
